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Abstract
Trichosporon yeasts constitute emerging pathogens, implicated in organ-speciﬁc and systemic infections. In this ﬁrst, comprehensive study of
Trichosporon clinical isolates in Greece, 42 isolates were identiﬁed by sequencing the hypervariable D1/D2 domain of the Large Subunit (LSU)
rDNA gene, while Trichosporon asahii were genotyped by sequencing the Intergenic Spacer 1 region, and antifungal susceptibilities were
determined by the EDef 7.2 (EUCAST) method, in parallel with the CLSI standard. Trichosporon asahii was the primary species (37 isolates)
followed by Trichosporon coremiiforme, Trichosporon dermatis, Trichosporon loubieri and Trichosporon mycotoxinivorans. One strain remained
unidentiﬁed. Seven T. asahii genotypes were recorded. The major genotypes were: genotypes 4 (29%) and 3 (26%) followed by 1, 5 and 7
(9.5% each). Two novel genotypes were identiﬁed designated as 10 and 11. EUCAST MIC ≥2 mg/L was recorded in 58% of the isolates
(amphotericin B), 41% (itraconazole), 41% (posaconazole) and 38% (voriconazole). Fluconazole MICs of ≥32 mg/L were recorded in 23.8%
of the isolates. Analysis of variance performed on absolute values showed that the amphotericin B, itraconazole, posaconazole and
voriconazole MICs of T. asahii were equivalent. Typically higher MIC values were displayed by ﬂuconazole. Antifungal susceptibilities of the
seven different genotypes were homogeneous. Agreements between EUCAST and CLSI ranged from 88.1 to 97.62%. Overall, the high MICs
recorded among the Trichosporon isolates for all tested drugs justify routine susceptibility testing of clinical isolates.
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Introduction
Members of the basidiomycetous yeast genus Trichosporon
constitute emerging opportunistic pathogens, implicated in
organ-speciﬁc (endocardium, gastrointestinal tract, meninges,
respiratory tract, skin, urinary tract and vagina) and systemic
infections [1]. They are also implicated in summer-type
hypersensitivity pneumonitis [2]. The incidence of invasive
Trichosporon disease is increasing, as its major patient tar-
get-groups—immunocompromised patients with haematolog-
ical disease or cancer and critically ill patients in intensive care
units—are continually growing [1,3]. Additionally, the genus
presents increased in vitro resistance to common antifungal
agents such as amphotericin B and echinocandins [4–6] and
strains resistant to multiple azoles have been identiﬁed [7].
Despite the increasing incidence of Trichosporon infections and
the increased antifungal resistance of the genus, there are few
reports on antifungal susceptibilities of clinical Trichosporon
strains, especially incorporating the newer Trichosporon
nomenclature [8]. Additionally, in our region, the distribution
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of Trichosporon species and genotypes in fungal disease and
their respective susceptibilities are unexplored domains.
In the present study, we accurately identiﬁed/genotyped a
collection of 42 Trichosporon clinical strains, isolated over the
past 9 years (2003–2011) in Greece, by sequencing the D1/D2
domain of the Large Subunit (LSU) rDNA gene and the IGS1
intergenic spacer. Additionally, we determined their suscepti-
bility to eight mainstay antifungal drugs by employing the
EUCAST EDef 7.2 standard method, recently revised for
antifungal susceptibility testing of non-fermentative yeasts such
as Cryptococcus spp. [9] and compared its performance with the
corresponding standard CLSI M27-A3.
Materials and Methods
Strains
We examined 42 Trichosporon clinical isolates collected from
patients in tertiary healthcare centres of Athens, Greece in
2003–2011. The isolates were recovered from blood (n = 7),
urine (n = 21), bronchial secretions or bronchoalveolar lavage
(n = 7), mucosal secretions (n = 2), pericardial ﬂuid (n = 1),
colonic biopsies (n = 1) and conﬁrmed nail infections (n = 3).
All strains were conﬁrmed as belonging to the genus Tricho-
sporon by morphology, assimilation studies (ΑΡI ID32C;
BioMerieux, Marcy l’Etoile, France) and by urease testing and
are cryopreserved in the Hellenic Collection of Pathogenic
Fungi (UOA/HCPF).
Molecular identiﬁcation
Isolates were revived by culture for 7 days in malt extract agar
at 30°C and DNA was extracted with a phenol–chloroform
method as described previously [10].
Identiﬁcation to species level was performed by partial
ampliﬁcation and sequencing of the D1/D2 domain of the LSU
rDNA gene, as previously described [11].
D1/D2-derived sequences (GenBank accession nos
JX111912–JX111953; http://www.ncbi.nlm.nih.gov/nucleotide/)
were compared with the GenBank-archived sequences
(BLAST; http://www.ncbi.nlm.nih.gov). Additionally, D1/D2-
derived sequences were aligned with CLUSTALW [12]. In
the alignments were included GenBank reference D1/D2
sequences (Fig. 1) representing the 37 acknowledged Tricho-
sporon species and phylogenetically closely related Cryptococcus
species [13]. Phylogenetic relations were derived via the
neighbour-joining method, the evolutionary distances were
computed using the Kimura two-parameter method [14] and
the robustness of the trees obtained was evaluated by 1000
bootstrap replications. Reference GenBank D1/D2 sequences
of the new species Trichosporon dohaense [8] were not included
in the phylogenetic analysis because of their short length but
they were compared with the derived sequences by separate
alignment. Alignments were constructed and phylogenetic
analysis was conducted using MEGA v.4 software [15].
Genotyping
All molecularly conﬁrmed Trichosporon asahii isolates were
genotyped by ampliﬁcation and sequencing of IGS1 using the
oligonucleotides 26SF and 5SR, as described previously [16].
IGS1-derived sequences (GenBank accessions no. JX111954–
JX111990) were aligned with reference GenBank Trichosporon
IGS1 from the nine recognized T. asahii IGS1 genotypes [16–
18] and a dendrogram was constructed as described above.
Antifungal susceptibility
Amphotericin B, ﬂuconazole, itraconazole, posaconazole, vo-
riconazole, anidulafungin, caspofungin andmicafunginMICswere
recorded using the recently revised EUCAST microdilution
method for yeasts (deﬁnitive document EDef 7.2; http://www.
eucast.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/AFST/
EUCAST_EDef_7_2_revision.pdf) and the CLSI standard
microdilution method for yeasts [9,19]. All compounds were
tested at concentrations 0.032–64 mg/L, at 35°C, without
agitation, and the control strains (Candida parapsilosis
ATCC2219 and Candida krusei ATCC6258) were used at each
independent trial. Reading was performed as per EUCAST and
CLSI guidelines, respectively.
Statistics
Statistical comparisons, performed on EUCAST derived MIC
absolute values, of amphotericin B and azoles for the T. asahii
isolates (n = 37) and T. asahii genotypes were made on
log-transformed data, by two-way analysis of variance (SPSS
v. 15.0; SPSS Inc., Chicago, IL, USA) followed by multiple
pairwise comparisons with Bonferroni corrections. Agreement
and intraclass correlation coefﬁcients (ICC) for log2-trans-
formed data obtained by the EUCAST and CLSI reference
methods for amphotericin B and the azoles against T. asahii
isolates were also calculated.
Results
Molecular identiﬁcation
In the studied population of 42 Trichosporon clinical isolates
from Greece ﬁve species were identiﬁed (Table 1), according
to the BLAST algorithm (score 99–100%) and conﬁrmed by
the constructed D1/D2 LSU rDNA dendrogram (Fig. 1).
Trichosporon asahii was the primary species (37 isolates, 88%),
followed by Trichosporon coremiiforme, Trichosporon dermatis,
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FIG. 1. Neighbour-joining tree generated from partial D1/D2 Large Subunit (LSU) rDNA-derived sequences of 42 clinical strains and reference
sequences of Trichosporon and related Cryptoccocus strains. Numbers above branches are bootstrap values.
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Trichosporon loubieri and Trichosporon mycotoxinivorans (one
isolate each, 2.4%). One strain (UOA/HCPF 7922), clustering
with Trichosporon faecale in the dendrogram, was not unequiv-
ocally identiﬁed as it presented a unique D1/D2 sequence
(Table 1).
Genotyping
Among the 37 T. asahii isolates, seven IGS1 sequence types/
genotypes were identiﬁed. The major genotypes were 4 (12
isolates, 29%) and 3 (11 isolates, 26%), followed by genotypes
1, 5 and 7 (four isolates each, 9.5%) (Table 1). Two of the
derived genotypes were distinct from the nine so far identiﬁed
and were accordingly designated as novel, genotypes 10 and 11
(Fig. 1). Genotype 10 (strain UOA/HCPF 9477; GenBank
accession no. JX111977) was phylogenetically close to geno-
type 1 from which it differed by one base. Similarly, genotype
11 (strain UOA/HCPF 14034; GenBank accession no.
JX111990) was close to genotype 4, also differing by one
base. Both these new genotypes were derived from strains
isolated from patients residing in western Greece (Ionian
Islands) without a travel history.
Antifungal susceptibility
EUCAST MIC reading was feasible after 24 h (absorbance 0.2),
whereas the CLSI protocol reading for 5/37 (13.5%) T. asahii
strains required 48 h of incubation for reliable reading. Also,
incubation for 48 h was required for our T. loubieri (1/1
isolate) and T. mycotoxinivorans (1/1 isolate) by the CLSI
method. Antifungal susceptibilities to amphotericin B and the
four azoles tested by the EUCAST and CLSI methods are
presented in Table 1. Trichosporon asahii isolates showed high
EUCAST-derived amphotericin B MIC (≥2 mg/L) in 58% of
cases (MIC range, geometric mean, MIC for 50% or 90% of the
isolates (MIC50/MIC90) shown in Table 2). The T. asahii
EUCAST azole performance was variable (Table 2); 84%,
41%, 41% and 38% of T. asahii isolates showed MIC ≥2 mg/L to
itraconazole, posaconazole and voriconazole, correspondingly,
whereas ﬂuconazole MICs ≥32 mg/L were recorded in 10/42
TABLE 1. Identiﬁcation, genotypes and antifungal susceptibilities of 42 clinical Trichosporon isolates
Strain identiﬁer
(UOA/HCPF
numbera) Origin
D1/D2 identiﬁcation
(IGS1 genotype)
Year of
isolation
MIC by EUCAST/CLSI (mg/L)
AMB FLZ ITZ POS VOR
3928 Bronchoalveolar lavage Trichosporon asahii (genotype 1) 2003 0.25/1 16/16 0.25/0.25 2/2 0.25/0.25
6316 Oropharyngeal swab T. asahii (genotype 7) 2005 0.064/0.125 16/16 4/4 2/2 0.5/0.5
7421 Urine T. asahii (genotype 4) 2005 32/16 16/8 0.5/0.5 4/2 8/4
7422 Urine T. asahii (genotype 1) 2005 32/16 16/16 1/1 4/2 4/4
7428 Urine T. asahii (genotype 7) 2006 0.5/1 16/32 0.5/0.5 16/8 1/1
7784 Urine T. asahii (genotype 3) 2006 16/8 64/32 8/4 2/1 2/1
7922 Bronchoalveolar lavage Trichosporon sp.c 2006 0.25/0.5 2/1 0.125/0.125 8/2 0.064/0.125
7928 Urine T. asahii (genotype 3) 2006 32/16 16/8 1/1 4/2 64/32
8049-1 Urine T. asahii (genotype 3) 2006 32/32 32/32 2/1 1/1 8/4
8049-2 Urine T. asahii (genotype 3) 2006 32/32 64/32 2/2 1/1 8/4
8049-3 Urine T. asahii (genotype 3) 2006 32/16 64/32 2/1 1/1 32/16
8049-4 Urine T. asahii (genotype 3) 2006 32/16 32/32 1/1 2/1 32/32
8049-5 Urine T. asahii (genotype 3) 2006 4/4 8/4 1/1 4/2 32/32
8049-6 Urine T. asahii (genotype 3) 2006 4/2 8/16 1/0.5 4/2 8/8
8108 Urine T. asahii (genotype 3) 2006 32/4 64/64 1/1 1/1 32/32
8148 Urine T. asahii (genotype 3) 2006 1/1 8/4 0.25/0.5 1/0.5 0.064/0.125
8257 Urine T. asahii (genotype 4) 2006 32/16 64/64 2/2 2/2 32/16
8381 Urine T. asahii (genotype 4) 2006 0.5/0.25 4/4 0.5/0.25 2/2 4/1
8520 Urine T. asahii (genotype 5) 2006 0.25/0.5 4/4 1/0.25 0.064/0.125 0.064/0.125
8658 Urine T. asahii (genotype 5) 2007 0.5/0.5 1/4 2/1 1/0.5 1/0.5
8659 Urine T. asahii (genotype 5) 2007 0.5/0.5 1/0.5 1/1 1/0.5 0.5/0.25
8720 Urine T. asahii (genotype 1) 2007 0.125/0.25 8/4 1/1 0.125/0.125 0.25/0.5
8739a Blood T. asahii (genotype 7) 2008 0.032/0.064 2/1 4/1 0.5/0.25 0.064/0.125
8739b Blood T. asahii (genotype 7) 2008 0.064/0.125 16/1 4/4 1/0.5 0.064/0.125
9477 Skin T. asahii (genotype 10b) 2007 8/4 2/4 0.5/0.5 1/0.5 1/0.25
9762 Blood T. asahii (genotype 5) 2008 8/4 2/2 32/32 32/16 1/0.25
9763 Blood T. asahii (genotype 4) 2008 4/2 16/16 32/32 32/4 4/4
9764 Blood T. asahii (genotype 1) 2008 1/2 4/4 2/1 32/4 0.5/0.25
9822a Blood T. asahii (genotype 4) 2008 1/2 16/16 0.5/1 0.25/0.25 1/0.5
9878-2a Urine T. asahii (genotype 4) 2008 2/4 2/2 16/32 4/2 2/2
9878-2b Urine T. asahii (genotype 4) 2008 1/1 1/1 16/32 2/1 1/1
10373 Blood T. asahii (genotype 4) 2008 2/2 8/4 1/0.5 2/1 1/0.5
10416 Faecal material Trichosporon coremiiforme 2008 0.5/0.5 4/1 0.25/0.125 0.5/0.125 0.5/0.5
11729 Pericardial ﬂuid Trichosporon dermatis 2010 2/2 0.25/0.5 0.25/0.5 0.5/1 0.032/0.032
12708 Bronchial secretions Trichosporon loubieri 2010 0.25/0.5 8/8 32/32 0.5/0.5 0.25/0.25
13584a Nails T. asahii (genotype 4) 2011 2/0.5 2/1 2/4 0.5/0.125 0.064/0.064
13584b Nails T. asahii (genotype 4) 2011 0.5/0.5 4/1 8/16 0.25/0.032 0.064/0.064
13600a Bronchoalveolar lavage T. asahii (genotype 4) 2011 8/2 8/64 4/8 0.5/1 0.25/0.25
13734 Nails T. asahii (genotype 3) 2011 1/1 64/64 2/4 4/2 1/1
13878 Bronchial secretions Trichosporon mycotoxinivorans 2011 2/1 32/32 32/32 0.25/0.5 1/1
13879 Oropharyngeal swab T. asahii (genotype 4) 2011 2/2 8/4 2/2 0.25/0.5 0.125/0.125
14034 Nasal secretions T. asahii (genotype 11b) 2011 0.5/0.5 32/32 32/32 0.5/0.5 2/2
aUniversity of Athens/Hellenic Collection of Pathogenic Fungi.
bIGS1 novel genotypes described in the present study.
cNot identiﬁed to species level due to its unique sequence; yet, closely related to T. faecale, T. coremiiforme or T. asahii.
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(23.8%) of the strains tested. Notably, 9/37 (24.3%) T. asahii
isolates displayed voriconazole MICs ≥8 mg/L. The T. asahii
echinocandin MIC values were overall high (MIC ≥8 mg/L), as
reported before [20,21] (detailed data not shown).
In general, T. asahii amphotericin B, itraconazole, posaco-
nazole and voriconazole susceptibilities were equivalent,
displaying low MIC absolute values (p <0.05). The MIC values
recorded against the seven T. asahii genotypes were not
statistically different (p <0.05). Agreement between the CLSI
and EUCAST results within 1 dilution for the drugs tested
were: amphotericin B, 92.86% (ICC, 0.781); ﬂuconazole, 88.1%
(ICC, 0.420); itraconazole, 97.62% (ICC, 0.743); posaconazole,
88.1% (ICC, 0.861); and voriconazole, 92.86% (ICC, 0.931).
Discussion
Fifteen Trichosporon species are currently regarded as poten-
tially pathogenic for humans. These comprise T. asahii, T. as-
teroides, T. coremiiforme, T. cutaneum, T. dermatis, T. domes-
ticum, T. faecale, T. inkin, T. japonicum, T. jirovecii, T. loubieri,
T. montevideense, T. mucoides, T. mycotoxinivorans [1,22] and
the recently described T. dohaense [8]. The present study
constitutes the ﬁrst survey on clinical Trichosporon isolates in
Greece, detecting ﬁve distinct species, with T. asahii compris-
ing the dominant isolate. This is consistent with reports on the
clinical dominance of T. asahii reported from Brazil, China,
Japan, Spain, Taiwan, Thailand and Turkey [4–6,16–18,20,23–
26]. Trichosporon asahii (senso lato), is the only Trichosporon
species previously reported in infections from our region [27].
Trichosporon mycotoxinivorans was only recently identiﬁed as a
novel respiratory pathogen in patients with cystic ﬁbrosis, as
only six such isolates derived from four patients have been
previously published [22]. Our isolate was similarly isolated
from a cystic ﬁbrosis patient with chronic airway colonization.
Currently, for the identiﬁcation of Trichosporon isolates from
culture to species level, alternative sequencing of conserved
genes (D1/D2 domain of the LSU rDNA) [28] or variable
non-coding regions such as Internal Transcribed Spacers 1 and
2 (ITS) or Intergenic Spacer 1 (IGS1) is recommended
[1,16,29]. Although the D1/D2 and ITS regions are each highly
homologous within the genus Trichosporon, they manage to
distinguish at least the 37 generally recognized Trichosporon
species [13], with the exception of T. montevideense and
T. domesticum, which have indistinguishable ITS sequences.
IGS1 is reported as presenting greater divergence than either
D1/D2 or ITS, and so is able to delineate all presently known
Trichosporon species [16]. Consequently, it has been success-
fully adopted for the identiﬁcation of clinical Trichosporon
isolates in a number of recent studies [16,18,20,23] although
its high intraspecies variability would probably make it rather
more appropriate for delineating genotypes within Trichosporon
species. This last point was corroborated in the present study
by the adequacy of D1/D2 for identifying all but one of our
clinical isolates. The unidentiﬁed strain UOA/HCPF 7922
clustered with T. faecale in the D1/D2 dendrogram and it also
presented a pattern consistent with T. faecale in a recent
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectroscopy study [30]. The strain needs further taxonomic
study as it may represent an as yet unrecognized species due
its unique D1/D2 sequence.
In total, nine T. asahii IGS1 genotypes have been described
so far from a number of countries such as Brazil, China, Japan,
Spain, Thailand, Taiwan, Turkey and the USA [16,20,23–24].
The ﬁrst seven genotypes constitute the major ones while
genotypes 8 and 9 have only been reported from Turkey [18].
The geographical distribution of the genotypes is variable [1].
In this ﬁrst study on the IGS1 T. asahii genotypes in Greece,
genotypes 3 (29%) and 4 (26%) were the predominant ones. In
contrast, the predominant genotypes in other areas were: 1
and 5 in the geographically proximal Turkey and in Spain, 1 in
Brazil, 1, 3 and 4 in China, and 1, 3 and 7 in Thailand. Generally,
genotype 3 has been previously reported as predominant only
in the USA (63.6%, albeit the population analysed was small—
only 11 isolates) and Thailand (34.7%) and genotype 4 only
from China (51.4%). The two novel genotypes, 10 and 11,
described in the present study, conﬁrm the large IGS1
intraspecies heterogeneity in T. asahii. In conclusion, IGS1
genotyping clearly remains a useful epidemiological tool for
T. asahii, although correlation with resistance to a particular
antifungal has not been substantiated before and it is also
highlighted in the present study.
TABLE 2. Minimum inhibitory concentration (MIC) ranges, geometric means (GM) and distributions for 50% (MIC50) and 90%
(MIC90) of 37 Trichosporon asahii isolates, determined by EUCAST and CLSI microdilution methods for yeasts
Method
Amphotericin B Fluconazole Itraconazole Posaconazole Voriconazole
MIC
range GM
MIC50/
MIC90
MIC
range GM
MIC50/
MIC90
MIC
range GM MIC50/MIC90
MIC
range GM
MIC50/
MIC90
MIC
range GM
MIC50/
MIC90
EUCAST 0.064–32 1.89 2/16 0.5–64 7.85 8/64 0.25–32 1.86 1/32 0.032–16 0.93 1/4 0.064–32 1.06 1/32
CLSI 0.032–64 1.91 2/32 1–64 8.55 8/64 0.25–32 1.94 2/32 0.064–32 1.44 1/4 0.064–32 1.07 1/32
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Amphotericin B, itraconazole, posaconazole and voriconaz-
ole appeared with similar activity against T. asahii. High
amphotericin B MICs have been reported previously
[5,18,21] although, as recent studies show, this is not a
universal trend [20]. The excellent in vitro proﬁle of vorico-
nazole has been well documented in previous studies
[7,18,20,23], even against amphotericin B, and other azole,
resistant isolates. High amphotericin B MICs have been
reported before for non-T. asahii isolates [5] in contrast to
the present study, but the small number of isolates tested
herein and in previous studies probably account for this
discrepancy. Reduced echinocandin activity, as observed in our
study, is a consistent ﬁnding in studies of in vitro antifungal
susceptibility of clinical Trichosporon isolates [18,23,25,31]. This
justiﬁes vigilance for breakthrough trichosporonosis, especially
in patients receiving echinocandin empirical treatment for
neutropenic fever [32,33].
Despite the limited Trichosporon species sample size avail-
able in our region for 2003–2011, the present ﬁndings show
random high MIC values distributed equally against T. asahii
isolates from deep and superﬁcial sites and non-T. asahii
isolates for all drugs tested. The variable results reported in
different susceptibility studies and the scarce data on the
correlation of in vitro susceptibilities with clinical outcomes
suggest that all clinical isolates should be tested.
Recently, to address concerns regarding impaired growth of
non-fermentative yeasts such as Trichosporon spp. in the
standard testing media, a number of modiﬁcations have been
suggested such as shaking during incubation, adoption of 30°C
instead of 35°C as incubation temperature, use of yeast
nitrogen base instead of RPMI, different inoculum sizes,
different glucose concentration (0.2% vs 2%) and supply of a
different nitrogen source (ammonium sulphate) [34]. The
recently revised document EUCAST EDef 7.2 incorporating
testing of the non-fermentative Cryptococcus spp. conﬁrmed
the improved growth obtainable due to these modiﬁcations
but found no signiﬁcant differences in the MICs recorded by
modiﬁed or standard EUCAST methods. Consequently, alter-
native use of 30°C incubation temperature in case of no
growth at 35°C was recommended for testing Cryptococcus in
the revised EUCAST standard. This would be useful for testing
other non-fermentative yeasts such as Trichosporon but in our
study it proved unnecessary as uniform good growth at 35°C
using the standard EUCAST method was observed, with the
exception of ﬁve T. asahii isolates and two non-T. asahii
isolates that appeared to be slow growers when following
the CLSI protocol, so requiring a 48-h reading instead of a 24-h
reading. The overall high recorded agreements between the
CLSI and EUCAST MIC results, ranging from 88.1 to 97.62%, in
conjunction with the high ICC suggest that both reference
methods give concordant MIC values for amphotericin B and
the azoles.
In conclusion, T. asahii is the dominant medically important
Trichosporon species in Greece, although rare species such as
T. coremiiforme, T. dermatis, T. loubieri, and T. mycotoxinivorans
also exist. The T. asahii isolates tested were equally susceptible
to amphotericin B, itraconazole, posaconazole and voriconaz-
ole. Additionally, MIC concordance was recorded for ﬂuco-
nazole by the EUCAST and CLSI protocols. Novel T. asahii
IGS1 genotypes exist in our region but antifungal susceptibil-
ities of different genotypes were homogeneous. The recorded
high MIC against local Trichosporon isolates warrant routine
susceptibility testing of such isolates, especially from immuno-
compromised patients. More interlaboratory-derived suscep-
tibility data of the known Trichosporon species from clinical and
environmental sources would assist in establishing clinical
breakpoints and corresponding epidemiological cut-off values
for these non-fermentative arthroconidial yeasts.
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